OS Therapies (OSTX) said Tuesday that it signed securities purchase agreements with investors to sell 1.5 million units at $4 each for gross proceeds of $6 million.
Each unit consists of one share of series A senior convertible preferred stock, initially convertible into one share of common stock and one warrant to purchase one common share. The preferred stock is convertible into shares at $4, while the warrants are exercisable at $4.40 per share, the company said.
The offering is expected to close on or about Friday.
OS Therapies said it will use the proceeds for working capital, particularly related to the clinical and regulatory milestones of lead therapeutic candidate OST-HER2 to treat recurrent, resected metastatic osteosarcoma in the US, and for general corporate purposes.
Shares of the company surged more than 17% in recent trading.
Price: 4.44, Change: +0.66, Percent Change: +17.46
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.